肾病综合征患者应用低分子肝素与卡托普利治疗的效果研究

阮晓玲

（金乡宏大医院，山东 济宁，272200）

浏览次数：125次 下载次数：346次

摘要：

目的 研究肾病综合征用低分子肝素与卡托普利治疗的效果。方法 选择2014 年9 月至2016 年11 月本院接收的肾病 综合征患者68 例，利用投掷子的方式将患者分为对照组（34 例，应用常规疗法）和试验组（34 例，在常规治疗基础上应用低 分子肝素与卡托普利）。观察对比两组患者的临床效果。结果 试验组治疗的总有效率为94.12%，高于对照组的73.53%（P<0.05）。试验组复发率为2.94%，低于对照组的17.65%（P<0.05）。治疗后，两组患者的总胆固醇、24 h 尿蛋白量水平降低，且试 验组低于对照组（P<0.05）；试验组患者的血浆白蛋白水平高于治疗前及对照组（P<0.05）。结论 对肾病综合征患者联合应用 低分子肝素与卡托普利，有助于其血总胆固醇、血浆白蛋白与24 h 尿蛋白等的快速改善，临床疗效十分显著。

关键词：低分子肝素；肾病综合征；卡托普利

中图分类号：R692.3文献标志码：A文章编号：2096-1413(2018)01-0026-02

Effect of low molecular weight heparin and captopril in the treatment of nephrotic syndrome
RUAN Xiao-ling
(Hongda Hospital of Jinxiang, Jining 272200, China)

ABSTRACT: Objective To study the effect of low molecular heparin and captopril in the treatment of nephrotic syndrome. Methods From September 2014 to November 2014, 68 cases of patients with ephrotic syndrome in our hospital were selected and divided into control group (34 cases) who received routine treatment and study group (34 cases) who accepted low molecular weight heparin and captopril on the basis of the routine treatment. The clinical effects of the two groups were observed and compared. Results The total effective rate of the study group was 94.12%, which was higher than 73.53% of the control group (P< 0.05). The recurrence rate was 2.94% in the study group, which was lower than 17.65% in the control group (P<0.05). After treatment, the total cholesterol and 24 h urinary protein levels decreased in both groups, and those of the study group were lower than the control group (P<0.05); the level of plasma albumin in the study group was higher than that before treatment and in the control group (P<0.05). Conclusion Low molecular weight heparin and captopril in the treatment of nephrotic syndrome can rapidly improve the total cholesterol, 24 h urinary protein and plasma albumin, which has significant clinical curative effect.

KEYWORDS: low molecular weight heparin; nephrotic syndrome; captopril

参考文献：
[1] 邓洪.低分子肝素联合卡托普利治疗肾病综合征的疗效分析[J].当代医学,2012,18(20):25.
[2] 余韩波,林俊川,胡晓辉,等.低分子肝素联合卡托普利治疗肾病综合征的临床疗效分析[J].中国实用医药,2014,9(18):9-11.
[3] 邱蕾.低分子肝素联合卡托普利治疗肾病综合征临床疗效分析[J].基层医学论坛,2017,21(2):187-188.
[4] 程宝连.卡托普利联合低分子肝素治疗肾病综合征的疗效分析[J].中国实用医药,2014,9(27):173.
[5] 邹雪军,洪玲.低分子肝素与卡托普利联合应用在51 例肾病综合征患者中的效果[J].当代医学,2015,21(27):150-151.
[6] 潘力行,陈圣炬.卡托普利联合低分子肝素治疗肾病综合征临床疗效分析[J].青岛医药卫生,2015,22(2):135-136.
[7] 汪靖婕.肾病综合征患者应用低分子肝素与卡托普利联合治疗的效果分析[J].海峡药学,2015,27(9):150-151.
[8] 石峰,刘勇,华瑞芳.低分子肝素联合卡托普利治疗肾病综合征的疗效观察[J].临床合理用药杂志,2016,9(31):62-63.
[9] 张大为.低分子肝素与卡托普利联合治疗肾病综合征的效果观察[J].中国现代药物应用,2016,10(19):162-163.
[10] 谭蔚越.联用低分子肝素和卡托普利治疗肾病综合征的效果评析[J].当代医药论丛,2016,14(7):110-111.
[11] 杨容华,郭桂琴.联合应用低分子肝素和免疫抑制剂治疗肾病综合征的疗效观察[J].当代医药论丛,2014,12(8):247-248.